Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Ensituximab |
Synonyms | |
Therapy Description |
Ensituximab (NEO-102) is a monoclonal antibody against a form of Muc5ac expressed in pancreatic and colorectal cancers, which may induce cytotoxic immune response against tumor cells (PMID: 27449137, PMID: 32303539). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Ensituximab | NEO-102 | Ensituximab (NEO-102) is a monoclonal antibody against a form of Muc5ac expressed in pancreatic and colorectal cancers, which may induce cytotoxic immune response against tumor cells (PMID: 27449137, PMID: 32303539). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|